天眼查App显示，近日，江西米玉泰岁生物有限责任公司成立，法定代表人为黄菲，注册资本333万人 民币，经营范围为许可项目：水产养殖，食用菌菌种生产，食用菌菌种经营，食用菌菌种进出口，食用 菌菌种质量检验，转基因种畜禽经营，种畜禽生产，牲畜饲养，种畜禽经营，家禽饲养（依法须经批准 的项目，经相关部门批准后在许可有效期内方可开展经营活动，具体经营项目和许可期限以相关部门批 准文件或许可证件为准）一般项目：农业科学研究和试验发展，食用菌种植，生物饲料研发，生物基材 料制造，生物基材料销售，生物农药技术研发，生物基材料技术研发，生物有机肥料研发，生物质成型 燃料销售，生物基材料聚合技术研发，水生植物种植，土地整治服务，中草药种植，专用化学产品制造 （不含危险化学品）（除依法须经批准的项目外，凭营业执照依法自主开展经营活动）。 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002496 证券简称：*ST辉丰 公告编号：2025-043 江苏辉丰生物农业股份有限公司 关于公司诉讼事项的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 江苏辉丰生物农业股份有限公司（以下简称"辉丰股份"或"公司"）近日收到江苏省盐城市中级人民法院 送达的民事裁决书（编号：（2024）苏09民初61号），现公告如下： 辉丰股份与北京航天关于承揽合同的纠纷。 诉讼事项的具体情况详见公司于2024年11月7日在指定披露媒体披露的《关于公司诉讼事项的公告》 （公告编号：2024-035）。 二、裁定的主要内容 辉丰股份因需要完善证据，向法院提出暂时撤回诉讼申请，盐城中院裁定：准许江苏辉丰生物农业股份 有限公司撤诉。案件受理费141800 元，减半收取70900元，由江苏辉丰生物农业股份有限公司负担。 三、其它尚未披露的诉讼仲裁事项 截止目前，公司没有其它应披露而未披露的重大诉讼、仲裁事项，一般诉讼 事项详见公司定期报告中 的相关章节。 一、诉讼事项的基本情况 1、诉讼当事人 原告：江苏辉丰生 ...

Core Viewpoint - The Guangzhou Baiyun District has launched a three-year action plan (2026-2028) to accelerate the high-quality development of the biomanufacturing industry, aiming to achieve an output value exceeding 50 billion yuan by 2028 and establish a nationally competitive biomanufacturing industry pilot zone [1][2]. Group 1: Industry Development Plan - The action plan outlines the construction of a "11221" industrial ecosystem, which includes the establishment of one biomanufacturing innovation center, one pilot base, two achievement transformation platforms, two phases of over 1,000 acres of biomanufacturing industrial parks, and a biomanufacturing fund cluster with a scale of 10 billion yuan [2][3]. - The biomanufacturing sector is recognized as a core area for cultivating new productive forces and is a strategic competitive point for the nation [1][2]. Group 2: Current Industry Landscape - Baiyun District is a significant hub for the cosmetics industry, with over 1,200 licensed cosmetics manufacturing enterprises, accounting for about 20% of the national total, and an industry scale projected to reach 36.14 billion yuan by 2024 [2]. - The biopharmaceutical industry in the region has surpassed 31.1 billion yuan, featuring leading companies such as Guangzhou Pharmaceutical Group and Hutchison Whampoa, fostering a collaborative development advantage through "leading enterprises + research empowerment + stock upgrading" [2]. Group 3: Industrial Park and Investment - The Guangzhou Baiyun Biomanufacturing Industrial Park, as a core component of the "11221" system, is crucial for spatial layout and cluster development, with the first phase covering approximately 450 acres focused on biomedicine, cell genes, and beauty products, while the second phase will cover about 900 acres across five major industry groups [3]. - A biomanufacturing industry fund cluster with a total scale of 10 billion yuan has been established, with the first phase raising 1 billion yuan, targeting investments across the entire lifecycle of biomanufacturing enterprises from startup to Pre-IPO [3].

Core Insights - The article highlights the development of a billion-level "Northern Bio Valley" in Dezhou, focusing on the growth of the biotechnology industry through collaboration and innovation [1][2][4] Industry Overview - Dezhou is concentrating on five key areas within the biotechnology sector: biomanufacturing, biomedicine, bio-agriculture, biomedical engineering, and biomass energy, aiming for high-end, clustered, and international development [2][3] - The city has established a clear framework for its biotechnology industry, with 153 enterprises in the sector and projected revenue of 40.4 billion yuan in 2024 [2] Innovation and Collaboration - Innovation is identified as the core driver for overcoming challenges and seizing development opportunities, supported by numerous national and provincial innovation platforms [3] - Dezhou has established long-term collaborations with over 40 universities and research institutions, holding nearly 300 patents related to biopreparation [3] Regional Development - Different regions within Dezhou are focusing on specific areas of biotechnology, such as biomanufacturing in Yucheng and medical devices in Qihe, creating a diverse and collaborative development landscape [4] - The city has mechanisms in place for regular roadshows and result transformation, targeting investors, entrepreneurs, and industry experts to facilitate efficient connections among technology, capital, market, and policy [4] Future Outlook - Dezhou aims to target cutting-edge fields such as synthetic biology, gene cell therapy, and AI pharmaceuticals, with plans to establish high-level innovation platforms and pilot bases [4] - The city is committed to enhancing its industrial cluster development, optimizing its industrial layout, and attracting leading enterprises and major projects to achieve the goal of becoming a billion-level "Northern Bio Valley" [4]

Group 1 - The 2025 Biomanufacturing Industry Conference was held in Guangzhou, focusing on the development of the biomanufacturing industry and gathering various stakeholders including government officials, industry experts, and investors [1][2] - The biomanufacturing industry is identified as a strategic emerging industry in China's 14th Five-Year Plan, with a target of reaching a total output value of approximately 500 billion yuan by 2027 and aiming for a trillion yuan scale by 2035 [2][3] - Guangzhou has established a dedicated working group for biomanufacturing development, aiming to create a competitive biomanufacturing industry cluster by 2027, focusing on five key areas: biomedicine, biomaterials, biological food, biomedicine, and biological agriculture [2][3] Group 2 - Huangpu District and Guangzhou Development Zone are positioned as the core areas for biomanufacturing, with a comprehensive policy support system established to facilitate the entire chain from R&D to industrialization [3][4] - The Guangzhou Frontier Biotechnology and Biomanufacturing Innovation Promotion Center was officially inaugurated, aiming to create a collaborative innovation platform involving government, industry, academia, and research institutions [4][5] - The conference featured various sessions on topics such as "Pharmaceutical Health and Beauty," "Agriculture, Food, and Materials Industry," and "Artificial Intelligence and Biomanufacturing Innovation," highlighting the innovative achievements of local enterprises [5][6] Group 3 - Local companies like Chuang'er Biotechnology and Muen Biotechnology showcased their innovative products, with Chuang'er receiving regulatory approval for its collagen product and Muen being recognized for its extensive microbial library [5][6] - Guangzhou aims to position biomanufacturing as a strategic pillar for high-quality urban development, attracting global biotech companies and top talent to foster innovation and create a globally influential biomanufacturing innovation hub [6]

Core Insights - The article discusses the rapid development and investment in the biomanufacturing sector in China, highlighting various projects and initiatives aimed at establishing mid-test platforms across multiple regions [5][6][12]. Investment and Project Developments - In Chongqing, a total of 32 projects with an investment of 14.53 billion yuan were signed, focusing on biomanufacturing, biomedicine, and other high-tech industries [5]. - The Chongqing Biomanufacturing Industry Pilot Platform aims to create a national-level mid-test platform for biomanufacturing, emphasizing intelligent biological fermentation and related technologies [6]. - The platform is part of a broader initiative that includes 1,252 key projects with a total investment of approximately 3.2 trillion yuan planned for 2025 [6]. Regional Initiatives - Changde Economic Development Zone is also advancing its synthetic biomanufacturing mid-test conversion platform, with significant construction progress reported [7][8]. - The Changde platform has a total investment of 169 million yuan and will feature multiple mid-test production lines to cater to various scales and types of biomanufacturing [8]. National Support and Policy Framework - Multiple provinces, including Guangdong, Shanghai, and Sichuan, are actively supporting the establishment of mid-test platforms, with specific funding and policy frameworks in place [10][11][12]. - The Ministry of Industry and Information Technology and the National Development and Reform Commission have set a goal to cultivate over 20 mid-test capability construction platforms by 2027, aiming to serve more than 200 enterprises [12].

Core Insights - China's bio-economy is showing a positive trend, with significant advancements in CAR-T cell therapy, original drug production, and brain-machine interface medical devices, positioning the country as the second-largest biopharmaceutical market globally [1][2] Industry Overview - The global bio-manufacturing industry is receiving heightened attention from major economies, with increased funding for genetic and cell engineering research, biomass utilization, and bio-based product development [2] - The number of CAR-T clinical research centers worldwide has grown to 2069 in 2024, a 60% increase from 1297 in 2020, with China hosting 388 centers, ranking second globally [2] - China has achieved a record high in the proportion of self-developed new drugs, with 93 new drugs approved by the National Medical Products Administration in 2024, marking a five-year peak [2] Research and Development - In 2024, China published over 20,000 SCI papers in the medical equipment field, leading globally in research output [3] - The bio-economy in China is characterized by a robust industrial foundation, with significant growth in the pharmaceutical and chemical sectors driven by advancements in synthetic biology and high-throughput screening technologies [3] Industry Transformation - The bio-industry is transitioning from "quantitative accumulation" to "qualitative leap," focusing on core technology breakthroughs, product quality upgrades, and enhancing supply chain resilience [4] - Notable innovations include the approval of the world's first "rice-derived" human serum albumin injection and the launch of the world's first 5.0T whole-body MRI system [4] Future Prospects - Innovations in synthetic biology and gene editing are driving rapid growth in bio-manufacturing, outpacing GDP growth, and positioning the bio-economy as a crucial sector in the future global economy [5]

Group 1 - The core viewpoint of the article is the announcement of the third batch of "Zhongguancun Characteristic Industrial Parks," with 24 new parks added, including 4 in Haidian District, focusing on innovative industries such as AI and robotics [1][2] - The "Zhongguancun Characteristic Industrial Parks" are recognized based on the management measures for the construction of characteristic industrial parks in the Zhongguancun National Independent Innovation Demonstration Zone, aimed at enhancing industrial innovation efficiency and promoting industrial cluster development [1][2] - The newly recognized parks in Haidian District include Zhongguancun (Haidian) Embodied Intelligence Innovation Industrial Park, Zhongguancun (Haidian) International Robotics Industrial Park, Zhongguancun AI Beiwai Community, and Zhongguancun Science City AI Digital Energy Industrial Park, each focusing on cutting-edge fields [1][2] Group 2 - Zhongguancun Science City AI Digital Energy Industrial Park covers a total building area of approximately 240,000 square meters, focusing on an "AI + energy infrastructure soft and hardware R&D testing platform" to provide comprehensive services from innovation R&D to application promotion [2] - Zhongguancun (Haidian) International Robotics Industrial Park is positioned as a strategic development hub for the robotics industry, integrating AI with new information technology, intelligent manufacturing, new materials, and biomedicine in a "1+4" industrial structure [2] - Zhongguancun (Haidian) Embodied Intelligence Innovation Industrial Park aims to create a comprehensive platform for technology R&D, industrial transformation, and innovation incubation, supported by top universities and research institutions [2] Group 3 - Previously, Haidian District has cultivated 9 characteristic parks, which serve as sources of technological innovation and incubators, linking international resources and nurturing high-growth tech companies [3] - The newly recognized parks will collaborate with the existing 9 parks to form an innovative cluster that enhances regional innovation development efficiency and promotes the internationalization and specialization of technology parks [3] - The efforts aim to establish Haidian as an international innovation hub, showcasing its openness and influence in the global innovation landscape [3]

Core Viewpoint - Hubei Fubon Technology Co., Ltd. reported a revenue growth of 6.50% in the first half of 2025, driven by strong performance in its modern agriculture business, and is focusing on integrating biological and digital technologies to enhance agricultural modernization [2][4]. Financial Performance - In the first half of 2025, the company achieved a revenue of 684.60 million yuan, an increase of 6.50% year-on-year [2] - Domestic revenue was 365.06 million yuan, up 5.10%, accounting for 53.32% of total revenue [2] - International revenue reached 319.54 million yuan, growing by 8.16%, making up 46.68% of total revenue [2] - Net profit attributable to shareholders was 61.22 million yuan, with net assets of 1.47 billion yuan, reflecting a year-on-year increase of 9.53% [2] R&D and Innovation - The company has established a comprehensive R&D innovation mechanism, maintaining investment in R&D to accelerate industrialization through demonstration verification and business model innovation [3] - In the modern agriculture sector, the company is developing a strain resource library, efficient fermentation processes, and field application technology [3] - Collaborations with academic institutions are ongoing to advance key projects in nitrogen fixation and nematode control [3][5] Strategic Layout - The company aims to empower global agriculture through biological and digital technologies, focusing on a dual-driven approach for agricultural modernization [4] - The biological agriculture sector is centered on four product areas, establishing a full-chain R&D system to promote large-scale application of products [4] - The digital agriculture sector emphasizes data-driven and intelligent decision-making, providing comprehensive products and services for precision agriculture [4] Agricultural Microbial Technology - The company collaborates with various agricultural universities and research centers to build a collaborative innovation system [5] - It utilizes laboratory platforms to screen nitrogen-fixing strains and jointly develops process innovations [5] Digital Agriculture Solutions - The company has launched digital agriculture solutions that integrate biological and digital technologies, focusing on cost reduction and yield increase [6] - A press conference is scheduled for March 2025 to unveil the "Agricultural Doctor" green agriculture brand [6] Auxiliary Business Development - The company is committed to developing efficient and environmentally friendly auxiliary products for fertilizers, collaborating with OCP Group on advanced project research [7] - A comprehensive solution for heavy metal remediation has completed small-scale customer testing and is moving towards industrial experimentation [7] AI Technology Application - The company is introducing advanced agricultural smart devices, particularly in digital soil testing and fertilization [8] - Projects include soil detection and big data, precision irrigation, and yield estimation using AI to enhance planting chain efficiency [8]

Group 1: Strategic Planning - The company aims to focus on "technological innovation, green development, and social return" as its strategic goals, emphasizing three major development directions: upgrading agricultural additives and specialty fertilizers, focusing on cost reduction and yield increase, and deepening the "going out" strategy in Southeast Asia, the former CIS, and Africa [2][3]. Group 2: Core Competitiveness - The company is committed to continuous technological innovation, developing biodegradable and environmentally friendly materials, and launching new agricultural additives that meet energy-saving and environmentally friendly requirements [4]. - Unique products and services in biological agriculture and digital agriculture have been introduced, providing comprehensive solutions for cost reduction and yield increase [4]. Group 3: Sales and Marketing Innovation - The company has implemented a "1+X" strategic marketing model, focusing on core customers while integrating traditional distributors, e-commerce platforms, and overseas exports [4][5]. - This model aims to provide customized, one-stop solutions, enhancing customer satisfaction and ensuring efficient business expansion [4]. Group 4: Risk Management - The company is expanding procurement channels in emerging markets to enhance supply chain resilience and flexibility, while maintaining reasonable inventory levels [6]. - Specific measures are in place to mitigate currency exchange risks, including shortening quotation cycles and increasing the proportion of direct RMB settlements [6]. Group 5: Business Development and R&D Progress - In the first half of 2025, the company achieved a revenue of 12,236.98 million yuan, a year-on-year increase of 13.31% [7]. - Significant investments in R&D have led to the launch of five new products for nematode control and three new products for nitrogen-fixing in the first half of 2025 [8]. Group 6: Future Mergers and Acquisitions - The company plans to pursue external development strategies, focusing on acquiring firms with core R&D capabilities in agricultural additives and specialty fertilizers [8]. - The dual-track acquisition strategy will also target technology-driven companies in gene editing and digital agriculture to enhance its service capabilities [8]. Group 7: R&D Investment and Innovation - The company has established a robust R&D innovation mechanism, ensuring sustained investment and breakthroughs in core technologies [9]. - Collaboration with top research institutions is emphasized to tackle key technologies and optimize the commercialization path [9][10].